Publikationen 2002
Weidmann E., Gramatzki M., Wilhelm M., Mitrou P.S.: Diagnosis and actual therapy strategies in peripheral T-cell lymphomas - a meeting report. Ann Oncol (2003) im Druck
Dittrich Ch, Greim G, Borner M, Weigang-Kohler K, Huisman H, Amelsberg A, Ehret A, Wanders J, Hanauske A, Fumoleau P. Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer. 2002 May;38(8):1072-80.
Sessa C, Weigang-Kohler K, Pagani O, Greim G, Mora O, De Pas T, Burgess M, Weimer I, Johnson R. Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule. Eur J Cancer. 2002 Dec;38(18):2388-96.
Sivakumaran M., Kunzmann V., Wilhelm M. Rituximab-induced tumor cell agglutination. Blood 100 (2002), 2672
Kraemer D., Rüdiger T., Reimer P., Müller-Hermelink H. K., Wilhelm M.
Splenectomy in patients with mixed myelodysplastic/ myeloproliferative disease. Ann Hematol. 81, (2002), 308-311.
Feurle J., Espinosa E., Eckstein S., Pont F., Kunzmann V., Fournié J.J., Herderich, M., Wilhelm M. E. coli produces phosphoantigens activating human gd T cells. J Biol Chem 277, (2002), 148-54
Kaiser G, Büschel G, Cebulla S, Michallik C Health Training for Cancer
Oral Presentation at the 11th Conference of the European Society for Psychosocial Oncology (ESPO-1), Heidelberg 2001
Büschel G & Horneber M. Clinical trials with mistletoe therapy in cancer. J Cancer Res Clin Oncol, 2002, Suppl 128, I200
Ritter E. [Vitamin supplements in oncology -- necessary, useful or superfluous?]
MMW Fortschr Med. 2002 Oct 10;144(41):33-7.
Bruntsch U. [Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)] MMW Fortschr Med. 2002 Sep 19;144(38):20.
